LNK-01002
- Generic Name
- LNK-01002
A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia
Phase 1
Withdrawn
- Conditions
- Primary MyelofibrosisAcute Myeloid LeukemiaPolycythemia VeraPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis
- Interventions
- First Posted Date
- 2021-05-21
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Lynk Pharmaceuticals Co., Ltd
- Registration Number
- NCT04896112
- Locations
- 🇺🇸
Revive Research Institute, Sterling Heights, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath